Apolipoprotein(a) Phenotypes and Their Predictive Value for Coronary Heart Disease: Identification of an Operative Cut-Off of Apolipoprotein(a) Polymorphism

Abstract

Background Apolipoprotein(a) isoforms of low-molecular weight are associated with coronary heart disease. However, because of the high number of apolipoprotein(a) isoforms, it is difficult to assess the cardiovascular risk linked to the apolipoprotein(a) gene of a subject; indeed a cut-off of apolipoprotein(a) polymorphism has not been established. The aim of this investigation was to identify an ‘operative’ cut-off that discriminates apolipoprotein(a) isoforms associated with high genetic risk for coronary heart disease.

Methods Two hundred and fifty-one patients with coronary heart disease and 284 controls were recruited. Apolipoprotein(a) isoforms were detected using a high-resolution phenotyping method.

Results Twenty-seven apolipoprotein(a) isoforms with apparent molecular weight varying from 280 to 820 kDa were identified. Several cut-offs of apolipoprotein(a) polymorphism were used in order to compare the frequencies of apolipoprotein(a) isoforms of low and high molecular weight between patients and controls: The cut-off between 640 and 655 kDa had the highest χ₂ (130.40). Even when possible differences in apolipoprotein(a) phenotypes (subjects with at least one isoform of low molecular weight and subjects with only isoforms of high molecular weight) were assessed, the same cut-off showed the highest χ₂ (122.47). Multivariate analysis showed that apolipoprotein (a) isoforms had the greatest predictive value for coronary heart disease (F value= 107.0720), when the cut-off between 640 and 655 kDa was used.

Conclusions The cut-off between 640 and 655 kDa appears to be the most efficient in identifying subjects at high cardiovascular risk linked to apolipoprotein(a) gene, since this cut-off discriminates apolipoprotein(a) isoforms expressing a greater risk for coronary heart disease. J Cardiovasc Risk 5: 37-42 © 1998 Lippincott-Raven Publishers.

Keywords

apolipoprotein(a)isoforms immunoblotting coronary heart disease lipoprotein(a)genetics

Get full access to this article

View all access options for this article.

References

Scanu

Fless

GM.

Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest 1990; 85: 1709–1715.

Ilyas Kamboh

Ferrel

Kottke

BA.

Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Genet 1991; 49: 1063–1074.

Geroldi

Bellotti

Buscaglia

Bonetti

Gazzaruso

Caprioli

Characterization of apo(a) polymorphism by a modified immunoblotting technique in an Italian population sample. Clin Chim Acta 1993; 221: 159–169.

Marcovina

Zhang

Gaur

Albers

JJ.

Identification of 34 apolipoprotein(a) isoforms: Differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun 1993; 191: 1192–1196.

Lackner

Cohen

Hobbs

HH.

Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993; 2: 933–940.

Boerwinkle

Leffert

Lin

Lackner

Chiesa

Hobbs

HH.

Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentration. J Clin Invest 1992; 90: 52–60.

Boerwinkle

Genetics of plasma lipoprotein(a) concentrations. Curr Opin Lipidol 1992; 3: 128–136.

Dahlen

Guyton

Attar

Farmer

Kautz

Gotto

AM.

Association of levels of lipoprotein(a), plasma lipid and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74: 758–765.

Rhoads

Dahlen

Berg

Morton

Dannenberg

AL.

Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986; 256: 2540–2544.

10.

Hoefler

Harnoncourt

Paschke

Mirti

Pfeiffer

Kostner

GM.

Lipoprotein Lp(a). A risk factor for myocardial infarction. Arteriosclerosis 1988; 8: 398–401.

11.

Loscalzo

Lipoprotein(a). A unique risk factor for atherothrombotic disease. Arteriosclerosis 1990; 10: 672–673.

12.

Kraft

Lingenhel

Kochl

Hoppichler

Kronenberg

Abe

Apolipoprotein(a) Kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 1996; 16: 713–719.

13.

Gazzaruso

Buscaglia

Garzaniti

Falcone

Mariotti

Savino

Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary heart disease in patients with essential hypertension. J Hypertens 1997; 15: 227–235.

14.

Buscaglia

Gazzaruso

Garzaniti

Bonetti

Fratino

Geroldi

Lipoprotein(a), apolipoprotein(a) polymorphism, and insulin treatment in type II diabetic patients. Diabetes Care 1995; 18: 1202–1203.

15.

Buscaglia

Gazzaruso

Garzaniti

Bonetti

Porta

Negri

Lipoprotein(a) and proliferative diabetic retinopathy in type II diabetes mellitus: A role for isoforms with low molecular weight. Diab Nutr Metab 1996; 9: 129–137.

16.

Gazzaruso

Buscaglia

Garzaniti

Bonetti

Savino

Mariotti

Lipoprotein(a) plasma concentrations, apolipoprotein(a) polymorphism and family history of coronary heart disease in patients with essential hypertension. J Cardiovasc Risk 1996; 3: 191–197.

17.

Gazzaruso

Bonetti

Garzaniti

Pini

Ragazzoni

Bianchi

: Increased plasma concentrations of Lipoprotein(a) for every phenotype of apolipoprotein(a) in patients with chronic renal failure treated by hemodialysis Nutr Metab Cardiovasc Dis 1996, 6: 203–210.

18.

Falcone

De Servi

Poma

Campana

Scire

Montemartini

Clinical significance of exercise-induced silent myocardial ischaemia in patients with coronary artery disease. J Am Coll Cardiol 1987; 9: 295–299.

19.

National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039–1057.

20.

1993 Guidelines for the management of mild hypertension. Memorandum from a WHO/ISH Meeting. ISH Hypertension News Special Edition, June 1993. pp. 3–16.

21.

Friedewald

Lewy

Fredrickson

DS.

Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.

22.

Wilcken

DEL

Dudman

NPB.

Effect of serum lipoprotein(a) on estimation of low density lipoprotein cholesterol by the Friedewald formula. Clin Chem 1994; 40: 571–573.

23.

Sandholzer

Boerwinkle

Saha

Tong

Utermann

Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: Evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest 1992; 89: 1040–1046.

24.

Sandholzer

Saha

Kark

Rees

Jaross

Dieplinger

Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 1992; 12: 1214–1226.

25.

Abe

Noma

Lee

Yamaguchi

Studies on apolipoprotein(a) phenotypes. Part 2. Phenotype frequencies and Lp(a) concentration in different phenotypes in patients with angiographically defined coronary artery diseases. Atherosclerosis 1992; 96: 9–15.

26.

Seed

Hoppichler

Reaveley

McCarthy

Thompson

Boerwinkle

Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990; 322: 1494–1499.

27.

Wild

Fortmann

Marcovina

SM.

A prospective case-control study of lipoprotein(a) and apo(a) size and risk of coronary heart disease in Stanford five-City project participants. Arteroscler Thromb Vasc Biol 1997; 17: 239–245.

28.

Marcovina

Albers

Wijsman

Zhang

Chapman

Kennedy

Differences in Lp(a) concentrations and apo(a) polymorphs between black and white Americans. J Lipid Res 1996; 37: 2569–2585.

29.

Lui

Lawn

RM.

Vascular interaction of lipoprotein(a). Curr Opin Lipidol 1994; 5: 269–273.

30.

Kang

Durlach

Soulat

Fournier

Angles-Cano

Lipoprotein(a) isoforms display differences in affinity for plasminogen-like binding to human mononuclear cells. Arterioscler Thromb Vasc Biol 1997; 17: 2036–2043.